Skip to main content
. 2013 Mar 31;4(4):550–559. doi: 10.18632/oncotarget.939

Figure 2. EGFR-TKI inhibits phosphorylation of molecules related to downstream signaling of EGFR.

HSC-3 and A549 cells treated with EGF and other drugs as indicated were analyzed on western blotting, using antibodies to the downstream signaling of EGFR, including pEGFR (175 kDa), EGFR (175 kDa), pSTAT3 (86 kDa), STAT3 (86 kDa), pAKT (60 kDa), AKT (60 kDa), pMAPK (42 and 44 kDa), and MAPK (42 and 44 kDa). β-Actin (43 kDa) served as an internal control.

Figure 2